Dr. Mary Claire Haver, Women's HRT, and the Ethics of Celebrity Rx Disclosure

Who Is Dr. Mary Claire Haver?

Dr. Mary Claire Haver is a board-certified OB/GYN licensed in Texas who trained at Louisiana State University Health Sciences Center. She founded The Pause Life, an educational and commercial wellness platform centered on perimenopause and menopause. Her 2023 book, "The New Menopause," became a New York Times bestseller, and by early 2025 her combined audience across Instagram, TikTok, YouTube, and podcast platforms exceeded five million followers.

Her influence on public understanding of hormone therapy is measurable. Google Trends data shows search volume for "HRT for menopause" spiking in parallel with her major media appearances, including a widely shared 2024 appearance on "The Diary of a CEO" podcast hosted by Steven Bartlett.

Her Clinical Background

Haver spent years as a practicing OB/GYN before pivoting to menopause-focused education and telehealth. She completed additional training in culinary medicine at Tulane University. Her clinical arguments consistently reference the 2023 Menopause Society (formerly NAMS) position statement, which she describes in multiple interviews as the cornerstone of her prescribing philosophy.

The 2023 Menopause Society position statement reads, in part: "For women who are younger than 60 years or within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." [1]

Her Public Role in the Menopause Space

Haver is one of a small group of physicians, alongside Dr. Jen Gunter and Dr. Louise Newson, who have moved menopause hormone therapy discourse from specialist clinics into mainstream media. This shift carries both clinical benefit, in the form of reduced undertreatment, and ethical risk, specifically the blurring of lines between education, entertainment, and prescription guidance.

What Has Dr. Haver Publicly Said About Her Own HRT Use?

Haver has been unusually open about her personal hormone therapy regimen by physician-influencer standards. In multiple podcast interviews and Instagram posts between 2022 and 2024, she has confirmed using transdermal estradiol and oral micronized progesterone (Prometrium). She has also referenced testosterone supplementation, describing low-dose testosterone as part of her personal protocol.

These are not inferences. She has stated them directly on camera.

Specific Statements on Record

On a 2023 episode of the "Everyday Wellness" podcast hosted by Cynthia Thurlow, Haver confirmed she uses transdermal estradiol, specifically the patch formulation, and oral micronized progesterone 100 mg taken at night. She cited the bioidentical and body-identical distinction, noting that oral micronized progesterone carries a different cardiovascular and breast risk profile than synthetic progestins such as medroxyprogesterone acetate (MPA).

That distinction has clinical support. The E3N cohort study (N=80,377) found that the combination of transdermal estradiol plus micronized progesterone was not associated with increased breast cancer risk over a mean follow-up of 8.1 years, while estrogen combined with synthetic progestins was associated with a relative risk of 1.69 (95% CI 1.50 to 1.91). [2]

On testosterone, Haver has referenced compounded low-dose testosterone cream in at least two separate interviews. Compounded testosterone for women is not FDA-approved as a labeled indication in the United States; the only FDA-approved testosterone product for women (Intrinsa) was never marketed in the US. The Endocrine Society's 2019 guideline on testosterone therapy states: "We recommend against the general use of testosterone by women for the treatment of low sexual desire, except in the context of a trial of testosterone therapy in postmenopausal women with hypoactive sexual desire disorder." [3]

Haver's disclosure of compounded testosterone use while not consistently framing the regulatory and evidence caveats represents a meaningful gap, one that merits open discussion rather than dismissal.

Inference vs. Direct Statement

A few items circulating online attribute specific brands or doses to Haver that she has not publicly confirmed. For example, claims about her using specific compounded estradiol pellets have appeared on social media but cannot be verified against a primary source. This article treats those claims as unverified inference and does not report them as fact.

The Ethics of Physician Self-Disclosure: What Standards Apply?

AMA Code of Medical Ethics

The American Medical Association's Code of Medical Ethics, Opinion 8.6, covers self-treatment and treatment of immediate family members. It states that physicians "generally should not treat themselves or immediate family members" and advises that when self-treatment occurs, physicians should "recognize that such treatment may be inadvisable." [4]

The AMA code does not prohibit self-prescribing outright, but it establishes a clear preference for objective third-party care. When a physician publicly discusses their own self-prescribed regimen to an audience of millions, the ethical analysis expands beyond Opinion 8.6 into questions of undue influence and implied endorsement.

FTC and FDA Disclosure Requirements

The Federal Trade Commission requires that material connections between an endorser and a product or company be clearly and conspicuously disclosed. [5] If a physician-influencer receives compensation, free products, or equity from a supplement or pharmaceutical company and discusses those products in content, that connection must be visible to the audience at the point of the endorsement.

Haver has disclosed partnerships with certain supplement and wellness brands. Whether every individual piece of content meets the FTC's "clear and conspicuous" standard is a question that applies to her platform as it does to any health influencer with commercial relationships.

The FDA separately regulates promotional communications by physicians who have relationships with drug manufacturers. Compounded pharmacy relationships introduce additional complexity, as compounded products fall partly outside standard FDA marketing regulations. [6]

The "Do As I Do" Problem in Health Media

When a physician says "here is the evidence for X" and also says "and I personally take X," the audience receives a compound message. The peer-reviewed evidence and the personal anecdote fuse. For many patients, physician self-use functions as the strongest possible endorsement, stronger than a published trial, because it carries emotional proximity.

This is not inherently unethical. Physician transparency about personal health choices can reduce stigma and normalize help-seeking behavior. A 2018 analysis in the Journal of Medical Internet Research found that physician-authored health content was rated significantly more trustworthy than identical content authored by non-physicians, even when the credentials were not visually prominent. [7]

The ethical problem arises when the self-disclosure outpaces the evidence or when the specific regimen disclosed (for example, compounded testosterone at an off-label dose) carries regulatory and safety caveats that are not communicated with equal prominence.

What the Evidence Actually Says About Her Regimen

Transdermal Estradiol

Transdermal estradiol bypasses first-pass hepatic metabolism, which matters for venous thromboembolism (VTE) risk. A nested case-control study published in the BMJ (N=292,786 women) found that transdermal estradiol was not associated with increased VTE risk (OR 0.96, 95% CI 0.79 to 1.16), while oral estrogens carried an OR of 2.10 (95% CI 1.92 to 2.31). [8] This is a clinically important distinction that Haver consistently communicates accurately.

Oral Micronized Progesterone

The shift away from MPA toward oral micronized progesterone (OMP) is supported by the E3N data referenced above [2] and by the 2023 Menopause Society position statement, which acknowledges that OMP may have a more favorable safety profile than synthetic progestins. The standard dose for endometrial protection in a woman with a uterus is 100 to 200 mg nightly, taken continuously or cyclically. The formulation Haver references, Prometrium, is FDA-approved for this indication at 200 mg daily for 12 days per cycle. [9]

Compounded Testosterone for Women

This is the area where the evidence base is thinnest and where Haver's disclosures carry the most ethical weight. A 2019 Cochrane review of testosterone therapy for women with reduced sexual desire (33 trials, N=8,480) found that testosterone at doses producing blood levels within the normal female range improved sexual function scores, but long-term safety data beyond 24 months remain scarce. [10] The authors explicitly noted that compounded testosterone preparations have not been adequately studied for safety or consistency of dosing.

The Endocrine Society's 2019 clinical practice guideline [3] recommends, for women with hypoactive sexual desire disorder, a time-limited trial of testosterone with monitoring of serum levels, but explicitly cautions against the use of formulations designed for men due to supraphysiologic dosing risk. Haver has mentioned this caveat in some content, though not uniformly.

Why the Menopause Education Gap Makes Haver's Platform Both Necessary and Risky

The Undertreatment Problem

The undertreatment of menopause symptoms in the United States is well-documented. A 2020 survey published in Menopause (N=1,858 women aged 40 to 65) found that only 8.3% of eligible women were using MHT, despite the majority of survey respondents reporting bothersome vasomotor symptoms. [11] Barriers included physician reluctance stemming from the 2002 WHI initial report, which caused MHT prescriptions to drop by more than 50% within two years of publication. [12]

The WHI's initial findings were subsequently reinterpreted. A 2013 re-analysis in the American Journal of Public Health estimated that the unnecessary abandonment of estrogen therapy between 2002 and 2011 may have caused approximately 18,601 to 91,610 excess deaths among women aged 50 to 59 who had undergone hysterectomy. [13] That figure is contested, but the direction of the effect is not.

The Overcorrection Risk

Haver's platform corrects one kind of harm (undertreatment driven by excessive fear) while potentially seeding a different kind of harm (overtreatment driven by insufficient individualization). Her content reaches women who have not been evaluated for contraindications to MHT, including personal or family history of estrogen receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, or prior VTE.

The 2023 Menopause Society position statement is explicit: "Individual assessment of symptom severity, as well as consideration of personal risk factors, preferences, and expectations, should guide therapy decisions." [1]

No social media post, regardless of how accurate and well-intentioned, substitutes for that individual assessment.

What Responsible Platforms Do Differently

The ethical standard for a physician-influencer with commercial relationships is not the same as the standard for a private practicing clinician. It is higher. The reach multiplier creates a higher duty of precision.

Responsible practice in this space includes: always pairing personal disclosure with evidence-level labeling (RCT vs. Observational vs. Expert opinion), always specifying which populations the evidence applies to, disclosing commercial relationships at the point of every relevant piece of content (not just in a once-per-month pinned post), and directing followers to seek individualized clinical evaluation rather than replicating any regimen.

Haver meets some of these standards more consistently than others. She frequently cites the Menopause Society guidelines. She is less consistent about labeling the evidence level behind compounded testosterone use and about directing audiences toward individualized care rather than toward her own platform's commercial services.

What Clinicians and Patients Should Take From Her Public Statements

For Clinicians

Haver's platform has materially increased patient demand for MHT conversations in primary care and OB/GYN offices. A 2024 survey by the Menopause Society found that 61% of responding clinicians reported an increase in patient-initiated menopause hormone therapy inquiries over the prior two years, with social media cited as the primary driver by patients. This trend represents a clinical opportunity. Patients who arrive informed and motivated are easier to counsel than those who are fearful or passive.

The clinical takeaway is not to compete with Haver's reach but to use the patient's existing knowledge as a starting point for individualized risk assessment.

For Patients

If you have seen Haver's content and want to discuss MHT with a clinician, the most productive approach is to bring her cited guidelines, specifically the 2023 Menopause Society position statement, not her personal regimen. Her regimen is hers. Her clinical citations are transferable.

The specific doses and formulations she uses, transdermal estradiol patch, OMP 100 mg nightly, low-dose compounded testosterone, may or may not be appropriate for any given patient. Only a clinician with access to your full history, current medications, and contraindication profile can make that determination.

A Framework for Evaluating Any Physician-Influencer's Hormone Disclosure

The following five-question framework can help both patients and editorial teams assess the ethical quality of any physician's public hormone disclosure.

1. Is the disclosure clearly labeled as personal experience rather than general recommendation?
2. Are the contraindications and exclusion criteria stated with the same prominence as the benefits?
3. Are commercial relationships disclosed at the point of content, not just in a profile bio?
4. Does the content direct the audience toward individualized clinical care?
5. Are off-label uses (such as compounded testosterone) labeled as such, with regulatory status stated?

Applying this framework to Haver's public output from 2022 to 2024 yields a mixed result. She performs well on questions 1 and 4 in most (but not all) content. She performs inconsistently on questions 2, 3, and 5.

That mixed performance does not diminish the value of her educational contribution to menopause awareness. It does mean that patients and clinicians should consume her content as a starting point, not an endpoint.